HALO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

394.63M

+32.42%

1.912

+51.75%

370.97M

+40.06%

1.810

+63.06%

397.66M

+22.09%

1.937

+25.76%

Estimates Revision

The market is revising No Change the revenue expectations for Halozyme Therapeutics, Inc. (HALO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 13.06%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+13.06%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 77.63 USD with a low forecast of 56.00 USD and a high forecast of 92.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

3 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

56.00

Averages

77.63

High

92.00

Current: 0.000

Low

56.00

Averages

77.63

High

92.00

Morgan Stanley

Overweight

downgrade

$79 -> $75

2026-01-08

New

Reason

Morgan Stanley

Price Target

$79 -> $75

2026-01-08

New

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on Halozyme to $75 from $79 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

TD Cowen

Buy

upgrade

$79 -> $90

2026-01-08

New

Reason

TD Cowen

Price Target

$79 -> $90

2026-01-08

New

upgrade

Buy

Reason

TD Cowen raised the firm's price target on Halozyme to $90 from $79 and keeps a Buy rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates "key for positioning within the sector recovery," the analyst tells investors in a research note. TD is most positive on stocks "with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions."

Goldman Sachs

Neutral -> Sell

downgrade

$56

2025-12-04

Reason

Goldman Sachs

Price Target

$56

2025-12-04

downgrade

Neutral -> Sell

Reason

Goldman Sachs downgraded Halozyme to Sell from Neutral with a $56 price target. A central debate for Halozyme is the long-term value of its Enhanze royalty model, which faces a substantial post-2030 revenue cliff as roughly 70% of royalties roll off contract between 2030-2035 and appears unlikely to be offset through typical business-development pacing, the analyst tells investors in a research note. Current valuation implies a terminal value that assumes roughly $34B in new partner product revenue by 2041, a level that seems achievable only under optimistic scenarios despite the recent Elektrofi acquisition, the firm says.

Goldman Sachs

Neutral

maintain

$54 -> $56

2025-11-18

Reason

Goldman Sachs

Price Target

$54 -> $56

2025-11-18

maintain

Neutral

Reason

Goldman Sachs raised the firm's price target on Halozyme to $56 from $54 and keeps a Neutral rating on the shares. Halozyme announced a global non-exclusive collaboration and license agreement with Merus to use Halozyme's Enhanze technology in the development of a subcutaneous formulation of petosemtamab, the analyst tells investors in a research note. While strategically positive, Goldman doesn't expect the announcement to meaningfully move the stock.

Citizens JMP

Outperform

maintain

$91 -> $92

2025-11-04

Reason

Citizens JMP

Price Target

$91 -> $92

2025-11-04

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Halozyme to $92 from $91 and keeps an Outperform rating on the shares. Halozyme reported a strong quarter driven by indication and global expansion of ENHANZE partnered products, the analyst tells investors in a research note. The firm expects Halozyme to achieve 2026 EBITDA of more than $1B, a milestone it would reach a year ahead of prior long-term guidance.

JPMorgan

Jessica Fye

Neutral

maintain

$63 -> $65

2025-10-27

Reason

JPMorgan

Jessica Fye

Price Target

$63 -> $65

2025-10-27

maintain

Neutral

Reason

JPMorgan analyst Jessica Fye raised the firm's price target on Halozyme to $65 from $63 and keeps a Neutral rating on the shares. The firm updated the company's model ahead of the Q3 report.

Valuation Metrics

The current forward P/E ratio for Halozyme Therapeutics Inc (HALO.O) is 9.25, compared to its 5-year average forward P/E of 14.66. For a more detailed relative valuation and DCF analysis to assess Halozyme Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

14.66

Current PE

9.25

Overvalued PE

19.41

Undervalued PE

9.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

13.62

Current EV/EBITDA

7.78

Overvalued EV/EBITDA

17.98

Undervalued EV/EBITDA

9.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

7.51

Current PS

5.21

Overvalued PS

10.47

Undervalued PS

4.55

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 4215.85% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

HALO News & Events

Events Timeline

No data

News

7.5

01-08PRnewswire

Halozyme Enters Exclusive Collaboration with Takeda for ENHANZE® Technology

7.5

01-08Newsfilter

Halozyme Enters Exclusive Collaboration with Takeda for ENHANZE® Technology

7.5

01-08Yahoo Finance

Halozyme and Takeda Sign Exclusive Collaboration for ENTYVIO Development

People Also Watch

Frequently Asked Questions

What is Halozyme Therapeutics Inc (HALO) stock price today?

The current price of HALO is 72.47 USD — it has increased 0.47 % in the last trading day.

What is Halozyme Therapeutics Inc (HALO)'s business?

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

What is the price predicton of HALO Stock?

What is Halozyme Therapeutics Inc (HALO)'s revenue for the last quarter?

Halozyme Therapeutics Inc revenue for the last quarter amounts to 354.26M USD, increased 22.12 % YoY.

What is Halozyme Therapeutics Inc (HALO)'s earnings per share (EPS) for the last quarter?

Halozyme Therapeutics Inc. EPS for the last quarter amounts to 1.43 USD, increased 36.19 % YoY.

What changes have occurred in the market's expectations for Halozyme Therapeutics Inc (HALO)'s fundamentals?

How many employees does Halozyme Therapeutics Inc (HALO). have?

Halozyme Therapeutics Inc (HALO) has 350 emplpoyees as of January 10 2026.

What is Halozyme Therapeutics Inc (HALO) market cap?

Today HALO has the market capitalization of 8.52B USD.